Pressure of Truth
Exposing the spin on all sides of the news.
Outlet track record

Endpoints News

U.S. biopharma trade, center

Endpoints News is a specialized trade publication covering the biopharmaceutical industry — drug development, business deals, regulatory decisions, and executive moves. Since April 2023 it has been majority-owned by the Financial Times, which is itself owned by Japan's Nikkei, Inc. Its coverage of the Trump administration focuses narrowly on how federal health and drug policies affect the biopharma sector, and it reports those impacts in a straightforward, industry-oriented way without an overt political slant.

Owned byMajority-owned by the Financial Times (itself owned by Nikkei, Inc.); co-founders Arsalan Arif and John Carroll retain minority stakes
LeaningU.S. biopharma trade, center
On the administrationmostly neutral
Full profile & history →
4average bias score across 1 story
1 = straight reporting · 10 = heavily spun

Stories